Articles with public access mandates - James BuchananLearn more
Available somewhere: 48
Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature
K Schwarze, J Buchanan, JC Taylor, S Wordsworth
Genetics in Medicine 20 (10), 1122-1130, 2018
Mandates: National Institute for Health Research, UK, Wellcome Trust
The challenge of antimicrobial resistance: what economics can contribute
LSJ Roope, RD Smith, KB Pouwels, J Buchanan, L Abel, P Eibich, ...
Science 364 (6435), eaau4679, 2019
Mandates: UK Economic and Social Research Council, National Institute for Health …
100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care—Preliminary Report
100,000 Genomes Project Pilot Investigators
New England Journal of Medicine 385 (20), 1868-1880, 2021
Mandates: US National Institutes of Health, Versus Arthritis, UK, Cancer Research UK …
The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom
K Schwarze, J Buchanan, JM Fermont, H Dreau, MW Tilley, JM Taylor, ...
Genetics in Medicine 22 (1), 85-94, 2020
Mandates: National Institute for Health Research, UK, Wellcome Trust
Issues surrounding the health economic evaluation of genomic technologies
J Buchanan, S Wordsworth, A Schuh
Pharmacogenomics 14 (15), 1833-1847, 2013
Mandates: Wellcome Trust
Methodological issues in assessing the economic value of next-generation sequencing tests: many challenges and not enough solutions
KA Phillips, PA Deverka, DA Marshall, S Wordsworth, DA Regier, ...
Value in Health 21 (9), 1033-1042, 2018
Mandates: US National Institutes of Health
Clomifene citrate and intrauterine insemination as first-line treatments for unexplained infertility: are they cost-effective?
S Wordsworth, J Buchanan, J Mollison, K Harrild, L Robertson, C Tay, ...
Human reproduction 26 (2), 369-375, 2011
Mandates: Chief Scientist Office, Scottish Executive
Valuation of health and nonhealth outcomes from next-generation sequencing: Approaches, challenges, and solutions
DA Regier, D Weymann, J Buchanan, DA Marshall, S Wordsworth
Value in Health 21 (9), 1043-1047, 2018
Mandates: Canadian Cancer Society
Availability and funding of clinical genomic sequencing globally
KA Phillips, MP Douglas, S Wordsworth, J Buchanan, DA Marshall
BMJ global health 6 (2), e004415, 2021
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Addressing challenges of economic evaluation in precision medicine using dynamic simulation modeling
DA Marshall, LR Grazziotin, DA Regier, S Wordsworth, J Buchanan, ...
Value in Health 23 (5), 566-573, 2020
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Welfarism Versus Extra-Welfarism: Can the Choice of Economic Evaluation Approach Impact on the Adoption Decisions Recommended by Economic Evaluation Studies?
J Buchanan, S Wordsworth
PharmacoEconomics 33 (6), 571-9, 2015
Mandates: National Institute for Health Research, UK, Wellcome Trust
Financing and reimbursement models for personalised medicine: A systematic review to identify current models and future options
R Koleva-Kolarova, J Buchanan, H Vellekoop, S Huygens, M Versteegh, ...
Applied Health Economics and Health Policy 20 (4), 501-524, 2022
Mandates: European Commission
Toward the diagnosis of rare childhood genetic diseases: what do parents value most?
S Pollard, D Weymann, J Dunne, F Mayanloo, J Buckell, J Buchanan, ...
European Journal of Human Genetics 29 (10), 1491-1501, 2021
Mandates: Genome Canada
A review of the challenges of using biomedical big data for economic evaluations of precision medicine
P Fahr, J Buchanan, S Wordsworth
Applied health economics and health policy 17 (4), 443-452, 2019
Mandates: National Institute for Health Research, UK
Patients’ Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment
J Buchanan, S Wordsworth, A Schuh
The Patient-Patient-Centered Outcomes Research 9 (6), 525-536, 2016
Mandates: National Institute for Health Research, UK, Wellcome Trust
Can rapid integrated polymerase chain reaction-based diagnostics for gastrointestinal pathogens improve routine hospital infection control practice? A diagnostic study.
L Pankhurst, L Macfarlane-Smith, J Buchanan, L Anson, K Davies, ...
Health technology assessment (Winchester, England) 18 (53), 1, 2014
Mandates: National Institute for Health Research, UK
Use of decision modelling in economic evaluations of diagnostic tests: an appraisal and review of health technology assessments in the UK
Y Yang, L Abel, J Buchanan, T Fanshawe, B Shinkins
PharmacoEconomics-open 3 (3), 281-291, 2019
Mandates: National Institute for Health Research, UK
Using “big data” in the cost-effectiveness analysis of next-generation sequencing technologies: challenges and potential solutions
S Wordsworth, B Doble, K Payne, J Buchanan, DA Marshall, C McCabe, ...
Value in Health 21 (9), 1048-1053, 2018
Mandates: National Institute for Health Research, UK
The impact of hospital costing methods on cost-effectiveness analysis: a case study
J Leal, S Manetti, J Buchanan
PharmacoEconomics 36, 1263-1272, 2018
Mandates: National Institute for Health Research, UK
How did a Quality Premium financial incentive influence antibiotic prescribing in primary care? Views of Clinical Commissioning Group and general practice professionals
AJ Borek, S Anthierens, R Allison, CAM McNulty, DM Lecky, C Costelloe, ...
Journal of Antimicrobial Chemotherapy 75 (9), 2681-2688, 2020
Mandates: UK Economic and Social Research Council, National Institute for Health …
Publication and funding information is determined automatically by a computer program